Novel Biomarker for Colorectal Cancer Identified through ABCE1 Research

Strategic Insights -

Researchers at Saveetha University have conducted a study to investigate the role of ABCE1 (ATP-binding cassette subfamily E member 1) as a potential biomarker for colorectal cancer (CRC). Through integrated bioinformatic analyses, the study highlights the significant oncogenic role of ABCE1 in CRC, opening new avenues for promising therapeutic interventions. The research demonstrates that deletion of ABCE1 can reduce cell growth, abrogate aerobic glycolysis, and promote apoptosis in HT-29 and HCT-116 cells. Furthermore, the study reveals a complex relationship between ABCE1 and the p53 signalling pathway, which was confirmed in experimental assays.

Key Takeaways:

  • ABCE1 is a potential biomarker for colorectal cancer, with a significant oncogenic role in CRC progression.
  • Deletion of ABCE1 can reduce cell growth, abrogate aerobic glycolysis, and promote apoptosis in HT-29 and HCT-116 cells.
  • The study demonstrates a complex relationship between ABCE1 and the p53 signalling pathway.
  • The effectiveness of ABCE1 inhibition, particularly through irinotecan, highlights its potential as a promising therapeutic option for colorectal cancer treatment.
  • The research provides comprehensive insights into the molecular mechanisms of ABCE1 in CRC progression and suggests its potential as a biomarker for CRC.
  • The study's findings have significant implications for the development of targeted therapies for CRC.
  • The research highlights the importance of ABCE1 as a potential biomarker in CRC and illuminates its complex molecular mechanisms.
  • The demonstrated effectiveness of ABCE1 inhibition, particularly through irinotecan, coupled with its interplay with crucial signalling pathways such as p53, highlights its potential as a promising therapeutic option for colorectal cancer treatment.

Statistics:

  • The study focused on two colorectal cancer cell lines (HT-29 and HCT-116).
  • The research demonstrated the effectiveness of ABCE1 inhibition through irinotecan in reducing cell growth and promoting apoptosis.
  • The study revealed a strong binding affinity of irinotecan for targets of the p53 signalling cascade through molecular docking analyses.
  • The research highlighted the potential of ABCE1 as a promising therapeutic option for colorectal cancer treatment.

Sources:

  • ABCE1 facilitates tumour progression via aerobic glycolysis and inhibits cell death in human colorectal cancer cells through the p53 signalling pathway. Scientific Reports, 2025,15(1):1-22.
  • Saveetha University.
  • NewsRx. Saveetha University Researchers Describe Research in Colon Cancer (ABCE1 facilitates tumour progression via aerobic glycolysis and inhibits cell death in human colorectal cancer cells through the p53 signalling pathway). Cancer Weekly. September 2, 2025; p 1268.